MarginsXMarginsX
Home › Markets › Health Care › IFRX

InflaRx N.V. (IFRX)

IFRX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.18
+0.85% on the day
Market cap
$173.9M
Micro cap
Revenue · 2025
$32K
-82.3% on 2024
Net income · 2025
-$50.4M
-155582.1% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1708688/000121390026032065/0001213900-26-032065-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLoss), fiscal year ended 2025-12-31. Converted from EUR at 0.9048 per USD (today's ECB or Federal Reserve reference rate).

Profile

FieldValue
TickerIFRX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryGermany
IPO year2017
SEC CIK0001708688
SEC industry codePharmaceutical Preparations
Incorporated inNetherlands

Financials · 2025

LineValue
Revenue$32K
Net income-$50.4M
Operating incomeNot in SEC XBRL data
Net margin-155582.1%
Operating marginOperating income not reported
Revenue growth-82.3%
Cash$17.7M
Total assets$61.0M
P/E (computed)Net income was not positive
P/S (computed)5364.4×

Reported in EUR; shown in US dollars.

Warning signs

Cash runway
5.4 months
16.0M EUR cash at December 31, 2025
Share count, 1 year
+21.8%
2024-12-31 to 2025-12-31 · +61.7% over 3 years
Going-concern doubt
Yes
20-F filed March 20, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"The Company is required to design the clinical trial phase 2b for its izicopan compound, obtain regulatory acceptance and determine the costs for the clinical trial phase 2b in order to seek substantial funding for continuing its operations which raises substantial doubt about its ability to continue as a going concern."
20-F 2026-03-20
Cash and burn16.0M EUR cash; operating cash flow -8.8M EUR a quarter.Report 2025-12-31
Shares outstandingNo cover-page share count in XBRLCover page 2025-12-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the marketLatest 2026-08-14
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG AG Wirtschaftspruefungsgesellschaft, Jena, GermanyPCAOB Form AP 2026-04-13
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
29K EUR-45.6M EUR-35.3M EUR16.0M EURNo debt tags29K EUR20-F 2026-03-20
FY 2024
2024-12-31
166K EUR-46.1M EUR-48.6M EUR18.4M EURNo debt tags166K EUR20-F 2026-03-20
FY 2023
2023-12-31
63K EUR-42.7M EUR-37.8M EUR12.8M EURNo debt tags63K EUR20-F 2026-03-20
FY 2022
2022-12-31
Not filed-29.5M EUR-33.7M EUR16.3M EURNo debt tagsNeeds four quarters20-F 2025-03-20
FY 2021
2021-12-31
Not filed-45.6M EUR-39.9M EUR26.2M EURNo debt tagsNeeds four quarters20-F 2024-03-21
FY 2020
2020-12-31
Not filed-34.0M EUR-36.5M EUR26.0M EURNo debt tagsNeeds four quarters20-F 2023-03-22
FY 2019
2019-12-31
Not filed-53.3M EUR-43.2M EUR33.1M EURNo debt tagsNeeds four quarters20-F 2022-03-24
FY 2018
2018-12-31
Not filed-29.8M EUR-21.5M EUR55.4M EURNo debt tagsNeeds four quarters20-F 2021-03-25

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months). Amounts in EUR.

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
425B5
424B52026-08-14
Latest annual report
ANNUAL REPORT
20-F2026-03-20
Latest quarterly / interim6-K2026-11-06

Source: SEC EDGAR submissions feed, 291 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-10.3%
1 month-24.5%
3 months-41.8%
Year to date+15.8%
1 year-7.9%
From 52-week high-57.3%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
KRROKorro Bio Inc.$12.71-6.61%$174.5M
WHWKWhitehawk Therapeutics Inc.$3.01-1.63%$177.6M
ANTXAN2 Therapeutics Inc.$4.47-1.76%$169.6M
ORMPOramed Pharmaceuticals Inc.$3.90+5.12%$169.6M
PYXSPyxis Oncology Inc.$1.41-10.76%$168.6M
SLGLSol-Gel Technologies Ltd.$54.96-0.29%$179.9M
PRQRProQR Therapeutics N.V.$1.18-16.31%$166.5M
ELDNEledon Pharmaceuticals Inc.$1.97-6.86%$166.4M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier